News from IMIM and CEXS-UPF
The five-year project, Enhancing Translational Safety Assessment through Integrative Knowledge Management (eTRANSAFE), aims to develop an advanced data integration infrastructure together with innovative computational methods to improve the security in drug development process and is funded by the Innovative Medicines Initiative 2 Joint Undertaking (IMI 2) together with the pharmaceutical industry.
The eTRANSAFE consortium is a private and public partnership of 8 academic institutions, 6 SMEs and 12 pharmaceutical companies, and is coordinated by the IMIM and led by the pharmaceutical company Novartis and Bayer AG. The project aims at improving the safety assessment across the drug discovery and development process by applying bioinformatics approaches to shared preclinical and clinical data to systematically analyse the translatability of effects. Thus, enabling the optimisation of resources and the development of safer medicines.
The group of Integrated Biomedical Computing of IMIM led by Laura Furlong will participate in activities of data integration, translational analysis and discovery of security biomarkers and Manuel Pastor, leader of the UPF's PharmacoInformatics group, will coordinate work groups in predictive modeling and software development.